Ellipticine is an established anticancer chemotherapeutic, however, its current method of synthesis requires many steps. MUSC researchers have developed a method to obtain ellipticine analogs in one step by utilizing radiation and an acid catalysis. The ellipticine family represents a class of natural products that have been used to develop potential treatments for cancer, HIV, and malarial infection. Recent communications have described rapid access approaches toward quninone4 and aza5 analogs from a common indoline core.
The invention provides for a novel approach of treating lung fibrosis related diseases (including scleroderma lung disease, idiopathic pulmonary fibrosis, interstitial pneumonia, asbestosis). Currently, there are no effective treatments available for these diseases. Upregulation of caveolin-1 was achieved by either infecting cells with adenovirus encoding the full-length caveolin-1 molecule or using a membrane-permeable peptide containing the caveolin-1 scaffolding domain (CSD). Control bleomycin-treated mice showed severe lung damage, whereas mice receiving CSD showed only slight ...
Commercially available devices for vagus nerve stimulation are implantable devices, requiring an invasive and expensive procedure. MUSC researchers are developing a noninvasive device that stimulates the vagus system incorporating ear electrodes with optimized pulses that can be tailored based on the condition to be treated (epilepsy, depression, stroke, tinnitus, etc.). This device is currently undergoing testing at MUSC (n=15) in order to show direct brain effects as investigated by functional magnetic resonance imaging.
Inventors at MUSC have developed a high-quality, packaged, e-learning module for goniometry applicable to physical and occupational therapy that incorporates multi-media (audio & video), interactive text, goal setting, and documentation. The modules cover goniometry for upper extremities and lower extremities including elbow, hand, scapula, shoulder, thumb, and wrist. Each extremity is further divided into specific flexions, such as adduction, abduction, and internal and external rotation, for which content is presented.
Intellectual Property Town Hall
Tuesday, November 1, 2016 - 3:30pm to 4:30pm
Bioengineering Building 110
Learn about changes to MUSC's Intellectual Property Policy and the impacy of those changes.
Michael G. Rusnak, Executive Director
MUSC Foundation for Research Development
Thomas Finnegan, Director
MUSC Center for Innovation and Entrepreneurship
Sponsored by the Faculty Senate Communications and Education Committee. Please contact Emily Brennan, email@example.com, with questions.
MUSC Cell Therapy Advisory Panel
October 25, 2016 - 8:00am to 12:30pm
Bioengineering Auditorium 110
Engage with industry experts
MUSC Foundation for Research Development (FRD) invites you to hear from cell therapy industry experts Ian Harris, PhD, Product Development Team Leader at Cell Therapy – Janssen Pharmaceutical R&D; Paul Williamson, MD, formerly of Johnson & Johnson, Therakos, and Centocor; Kathy Tsokas, JD, Sr. Director Regulatory Affairs – Johnson & Johnson; and representatives from Cook Regentec.
SC SoPE (Society of Physician Entrepreneurs) Chapter Meeting
The next SC SoPE (Society of Physician Entrepreneurs) Chapter meeting on October 27th at 6 PM at the Irene Dixon Auditorium. The auditorium is located on the first floor of the Roper Hospital (316 Calhoun Street, Charleston SC 29401). To learn more about SoPE visit https://www.sopenet.org/.
There will be 2 physician entrepreneurs speaking on the clinical need behind their invention, how they came up with the invention, what successes and struggles they have faced along the way, and where they stand now. We will conclude with a presentation by John Osborne, Co-founder and Director of The Harbor Entrepreneur Center http://www.harborec.com/ and Executive Administrator of Charleston Angel Partners http://www.chapsc.com/. He will give an overview of both The Harbor and Charleston Angel Partners and explain how both could be amazing resources for physician entrepreneurs.
DeLegge Medical will be providing snacks and beverages for the meeting!
Please RSVP by October 24th to Lauren@DeLeggeMedical.com or Chelsea Ex-Lubeskie, Licensing Manager at MUSC FRD firstname.lastname@example.org
Neuroene Therapeutics Awarded $225,000 STTR Research Grant
Startup rooted in MUSC investigators’ efforts to find new anti-seizure drugs
Charleston, S.C. (Aug. 24, 2016) – Neuroene Therapeutics, a startup company born from unique research by two Medical University of South Carolina (MUSC) investigators, secured a Small Business Technology Transfer (STTR) grant for $225,000 in July from the National Institute of Neurological Disorders and Stroke (NINDS).
Neuroene Therapeutics is using the Phase I STTR grant to help further develop a novel class of compounds for treating epilepsy. In the U.S. alone, epilepsy’s estimated direct and indirect costs total $15.5 billion, according to the Health and Medicine Division of the National Academies of Sciences.
SCTR Technology Development Grant Awardees
Congratulations to Nathan Dolloff, Ph.D. and James Chou, Ph.D. on receiving the most recent SCTR technology development grants.
James Chou, Ph.D.'s research focus is centered around the neuro-vitamin K (VK) synthase UBIAD1, which has recently been identified through a forward genetic screen as a dominant enhancer of the Parkinson’s disease (PD) establishing an additional link among mitochondria, vitamin K, and PD pathogenesis. Supplementation of VK reverses the non-flight phenotype observed in the drosophila model. Unfortunately, for humans, neuronal VK requires a series of metabolic processes and direct synthesis by UBIAD1 in the central nervous system in situ, and cannot be supplemented through dietary means. We have developed VK analogs that can easily penetrate blood-brain barrier and showed effective in the chemical induced PD model. The SCTR-FRD Grant will allow the optimization of the lead drug candidate’s dosing routine instead of performing the costly efficacy experiments blindly. With the funded study, it will also significantly move the project forward for future efficacy studies.
MUSC, Harbor Entrepreneur Center to launch life-science tech accelerator in Charleston
Charleston’s growing medical technology industry will be the focus of a new accelerator program launching this fall.
The program, called PriMed, aims to give a boost to startups that make products like medicines and medical devices when it takes in its first group of companies in September.
The initiative is a collaboration between the Harbor Entrepreneur Center, which runs an accelerator for traditional tech startups, and the Medical University of South Carolina’s Foundation for Research Development, which helps make the school’s inventions commercially available.
FRD Welcomes Two New Board Members
The MUSC Foundation for Research Development (FRD) welcomes two new board members. These two new members exemplify innovation and development and will be a great asset to the Foundation. Welcome!
Dr. Robert D. McQuade
Ph.D. | Biochemistry, UNC
Currently Executive Vice President and Chief Strategic Officer at Otsuka Pharmaceuticals Development and Commercialization.
Dr. Paul Williamson
M.D | University of Massachusetts
MUSC Start-Up Wins Prestigious National Award
Congratulations to ToleRaM Nanotech, LLC for winning a National TechConnect Innovation Award, which is meant to recognize innovative technology that has the potential to make a difference in a special sector, such as medicine. Only 15% of submitted entries receive the prestigious award.
Click here for more information.
Charleston Celebrates Entrepreneurship
We had a great turnout at the "Charleston Celebrates Entrepreneurship" event on Friday, April 22nd. Speakers included Dr. Cam Patterson from New York-Presbyterian Hospital/Weill Cornell Medical Center, and MUSC's very own Dr. Bart Sachs. Mayor John Tecklenberg reinforced his commitment to entrepreneurial growth here in Charleston.